Quent Long Short Global Small Cap Fund LP Makes New $2.20 Million Investment in Amgen Inc. $AMGN

Key Points

• Quent Long Short Global Small Cap Fund LP initiated a new position in Amgen, buying 6,731 shares in Q4 valued at approximately $2.20 million.
• Multiple large institutions (e.g., Capital World Investors, National Bank of Canada FI, VanEck, Fisher Asset Management) boosted their Amgen holdings, leaving about 76.50% of the stock owned by institutional investors and hedge funds.
• Amgen recently beat quarterly expectations (Q4 EPS $5.29 vs. $4.76; revenue $9.87B), issued FY‑2026 EPS guidance of 21.60–23.00, and declared a quarterly dividend of $2.52 ($10.08 annual, ~2.9% yield).

Quent Long Short Global Small Cap Fund LP bought a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 6,731 shares of the medical research company's stock, valued at approximately $2,203,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Capital World Investors boosted its holdings in shares of Amgen by 11.5% in the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company's stock worth $5,303,578,000 after buying an additional 1,935,876 shares during the period. National Bank of Canada FI boosted its position in shares of Amgen by 237.7% in the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company's stock worth $346,076,000 after buying an additional 863,216 shares during the period. Van ECK Associates Corp boosted its position in shares of Amgen by 71.8% in the third quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company's stock worth $383,254,000 after buying an additional 567,400 shares during the period. Fisher Asset Management LLC boosted its position in shares of Amgen by 91.6% in the third quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company's stock worth $221,607,000 after buying an additional 375,463 shares during the period. Finally, Danske Bank A S acquired a new stake in shares of Amgen in the third quarter worth $101,076,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Completed early-stage cancer study — Amgen announced completion of a Phase 1/2 MTAP‑null cancer combination study, a pipeline de‑risking milestone that could support long‑term value if follow‑up data are positive. Amgen Marks Key Milestone With Completion of Early MTAP-Null Cancer Combo Study
• Positive Sentiment: Analyst price‑target lift — Guggenheim nudged its price target to $351 (from $347) ahead of earnings, a modest endorsement that may support the stock despite the firm keeping a Neutral rating. Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings
• Neutral Sentiment: CTO retirement and leadership realignment — Amgen announced David M. Reese, M.D. will retire as EVP & Chief Technology Officer effective June 30, with a strategic leadership realignment emphasizing integration of biology and technology; operationally notable but framed as orderly. AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
• Neutral Sentiment: New/maintained Hold coverage — Bernstein and Canaccord Genuity are on Hold for AMGN (Canaccord initiated coverage with a Hold), indicating limited near‑term analyst conviction. Amgen (AMGN) Receives a Hold from Bernstein Canaccord Genuity initiates coverage of Amgen (AMGN) with hold recommendation
• Negative Sentiment: Q1 earnings expected to decline — previews from Zacks/Yahoo suggest Amgen lacks the setup for an earnings beat in the upcoming Q1 report, creating downside risk around the release. Earnings Preview: Amgen (AMGN) Q1 Earnings Expected to Decline
• Negative Sentiment: Insider selling — filings show roughly US$4.1M of insider share sales over the past year, which some investors interpret as a cautionary signal. Amgen Insiders Sell US$4.1m Of Stock, Possibly Signalling Caution

Analyst Ratings Changes

Several analysts have recently commented on the company. TD Cowen reaffirmed a "buy" rating on shares of Amgen in a research report on Wednesday, February 4th. Morgan Stanley raised their target price on Amgen from $309.00 to $326.00 and gave the stock an "equal weight" rating in a research report on Friday, April 10th. Freedom Capital cut Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 12th. Cantor Fitzgerald restated a "neutral" rating and set a $350.00 price target on shares of Amgen in a report on Wednesday, April 8th. Finally, Jefferies Financial Group began coverage on shares of Amgen in a report on Tuesday, March 10th. They set a "hold" rating and a $350.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $356.62.

Amgen Price Performance

NASDAQ AMGN opened at $348.62 on Friday. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The stock has a market capitalization of $188.14 billion, a PE ratio of 24.50, a price-to-earnings-growth ratio of 3.62 and a beta of 0.47. The company has a 50 day moving average price of $361.24 and a two-hundred day moving average price of $338.80. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion during the quarter, compared to analysts' expectations of $9.46 billion. During the same period in the previous year, the company earned $5.31 earnings per share. The company's revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts predict that Amgen Inc. will post 22.18 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. Amgen's payout ratio is currently 70.84%.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.